$2.66
+0.00 (+0.00%)
Open$2.67
Previous Close$2.66
Day High$2.72
Day Low$2.63
52W High$8.54
52W Low$2.29
Volume—
Avg Volume327.0K
Market Cap121.07M
P/E Ratio—
EPS$-0.85
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+101.9% upside
Current
$2.66
$2.66
Target
$5.37
$5.37
$3.28
$5.37 avg
$6.50
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 9.1K | 101.5K | 62.40M |
| Net Income | -39,356,566 | -394,881,933 | -13,759,336 |
| Profit Margin | -401,812.5% | -381,721.9% | -22.1% |
| EBITDA | -40,362,441 | -427,472,897 | -15,040,886 |
| Free Cash Flow | — | — | -13,384,851 |
| Rev Growth | -91.0% | -91.0% | +12.2% |
| Debt/Equity | — | — | 0.54 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |